Background: Valproic acid is considered as a promising anti-cancer therapeutic agent acting on unfolded protein response. SEL1L is an UPR-responsive gene. Results: SEL1L interference synergy enhances VPA cytotoxic effects on glioma stem cells. Conclusion: VPA treatment combined with SEL1L depletion may influence GSC pharmacological response. Significance: Targeting SEL1L in association with valproic acid treatment may improve glioma treatment.
Valproic acid (VPA), an histone deacetylase inhibitor, is emerging as a promising therapeutic agent for the treatments of gliomas by virtue of its ability to reactivate the expression of epigenetically silenced genes. VPA induces the unfolded protein response (UPR), an adaptive pathway displaying a dichotomic yin yang characteristic; it initially contributes in safeguarding the malignant cell survival, whereas long-lasting activation favors a proapoptotic response. By triggering UPR, VPA might tip the balance between cellular adaptation and programmed cell death via the deregulation of protein homeostasis and induction of proteotoxicity. Here we aimed to investigate the impact of proteostasis on glioma stem cells (GSC) using VPA treatment combined with subversion of SEL1L, a crucial protein involved in homeostatic pathways, cancer aggressiveness, and stem cell state maintenance. We investigated the global expression of GSC lines untreated and treated with VPA, SEL1L interference, and GSC line response to VPA treatment by analyzing cell viability via MTT assay, neurosphere formation, and endoplasmic reticulum stress/UPR-responsive proteins. Moreover, SEL1L immunohistochemistry was performed on primary glial tumors.
The results show that (i) VPA affects GSC lines viability and anchorage-dependent growth by inducing differentiative programs and cell cycle progression, (ii) SEL1L down-modulation synergy enhances VPA cytotoxic effects by influencing
GSCs proliferation and self-renewal properties, and (iii) SEL1L expression is indicative of glioma proliferation rate, malignancy, and endoplasmic reticulum stress statuses. Targeting the proteostasis network in association to VPA treatment may provide an alternative approach to deplete GSC and improve glioma treatments.
Although cancer has traditionally been considered as a disease originating from genetic and chromosomal alterations, epigenetic modifications or gene expression modulation through mechanisms other than changes in the underlying DNA sequence have emerged as contributing factors toward oncogenesis (1) . Based on the central role of histone deacetylase inhibitors to influence chromatin structure, they represent a new class of anticancer drugs with the potential to revert aberrant epigenetic states associated with cancer (2) . Histone deacetylase inhibitor, by increasing histone acetylation, give rise to a more permissive or open chromatin configuration leading to the potential reactivation of aberrantly suppressed genes, resulting in growth arrest, cell differentiation, and apoptosis of tumor cells (3) (4) (5) (6) . Among several histone deacetylase inhibitors, valproic acid (VPA), 2 is currently being used as an anticancer agent in several clinical trials (7) either as a monotherapy (8) or in conjunction with other treatments such as chemotherapy or radiation (9) . Moreover, VPA has a protective effect on cardiomyocite hypertrophy, the primary adaptive response to exogenous physiological or pathological signals (10) .
The potential role of VPA in directly regulating the unfolded protein response (UPR) through acetylation of its central regulatory protein Bip was recently reported (11) ; however, the functional consequence of VPA-induced Bip acetylation as well as the translational potential in clinical settings has yet to be established. UPR is a conserved adaptive cellular response that aims at relieving proteostasis defects by (i) attenuating the rate of protein synthesis, (ii) up-regulating protein folding enzymes, and (iii) activating the endoplasmic reticulum-associated degradation machinery and secretory capacity (12) . Finally, if homeostasis cannot be restored, death/senescence programs are activated (12) . It represents a "yin-yang" cancer process; early response is cell protective and supports chemoresistance (yang), whereas extensive activation turns on cell death program (yin) (13) . These temporally distinct pro-survival/proapoptotic waves may provide therapeutic opportunities; indeed blocking adaptive and enhancing contra-adaptive signaling pathways could drastically contribute to cancer therapy (13) .
UPR finely orchestrates the endoplasmic reticulum-associated degradation pathway, a temporally and spatially coordinated surveillance process charged with clearance of aberrant proteins in the ER by (i) substrate selection, (ii) dislocation across the ER membrane, and (iii) covalent conjugation with polyubiquitin and proteasomal degradation (14) . SEL1L is an ER-embedded adaptor that links substrate recognition to the E3 ligase-coupled dislocation apparatus (15, 16) . Considering its accurate timing and control in the proteolysis of key regulators as well as its position between two critical homeostatic pathways, SEL1L regulates several cellular functions and programs including cell fate developmental decision and homeostasis. It plays an essential role in maintaining ER homeostasis during vertebrate embryonic development (17) and in the maintenance of neural progenitor state and lineage determination (18) . Based on its role in these critical cellular processes, subversion of SEL1L has been linked to important diseases including neurodegeneration and cancer. Interestingly, its expression is dependent on tumor context, being down-modulated in pancreatic and breast adenocarcinomas (19 -21) and up-regulated in prostatic cancer (22, 23) and metastasis (24) . Generally, it is up-regulated during the initial phases of neoplastic transformation, underlying a potential biomarker function in tumor progression (24 -27) . Moreover, the protein subcellular localization is able to distinguish lung cancer subtypes (27) .
Considering its implication in neural stem cell and tumor biology as well as its potential link with UPR-dependent regulation by VPA, we explored the functional effect of SEL1L in GSC and its contribution in influencing stem cell drug sensitivity. Here we show the correlation between SEL1L, proliferation, and Ki-67 expression both in vitro and in vivo glioma model systems. Moreover, using silencing technology employed with short term survival and neurosphere assays, SEL1L emerges as a potential determining factor of GSC sensitivity to VPA treatment.
EXPERIMENTAL PROCEDURES
Cell Lines Growth Conditions, Nucleofection, and VPA Treatment-GSC lines (G166, G179, and GliNS2, kindly provided by Professor Austin Smith) and GBM2 and GBM7 (provided by Dr. Antonio Daga) were grown as described (28 -30) .
G179 cells (1 ϫ 10 6 ) were transiently nucleofected with 100 pmol of two small interference RNAs (siRNAs) against the 5Ј end of the SEL1L coding sequence and one non-targeting siRNA (NT siRNA) (Ambion, Monza, Italy) using the Nucleofector and Amaxa nucleofector kit V (Lonza). GSC lines were treated with VPA (2 mM) (Sigma) for 96 h in all experiments. Two SEL1L-siRNAs were used to guarantee the minimal or no off-target activity and the reliability of the silenced phenotype.
qPCR Analysis-Total RNA was purified using TRI Reagent solution (Applied Biosystems) and reverse-transcribed with SuperScript TM II reverse transcriptase (Invitrogen).
RT-qPCR was performed in triplicate on Rotor-GeneQ (Qiagen) using SYBR Green (Fermentas) detection. Data were normalized to hypoxanthine-guanine phosphoribosyltransferase expression using the ⌬⌬Ct method. Data are the averages of three independent experiments. See Table 1 for primer sequences.
Western Blotting-GSC lines were lysed in 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Nonidet P-40 containing protease inhibitors (Pierce). Samples were resolved on SDS-polyacrylamide gels (10%), blotted onto PVDF membranes, and probed with anti-SEL1L (32) and anti-vinculin (Sigma) in Xblot-100 as hybridization chamber. Filters were developed with ECL (Genespin). Densitometric analysis was determined using the Scion imaging program. Data are the average of two independent experiments.
Immunofluorescence-Cells were fixed in 4% paraformaldehyde for 15 min, treated for 10 min with 0.1 M glycine, and 
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incubated for 30 min at room temperature in blocking solution. Cells were immunostained overnight at 4°C in blocking solution with mouse anti-SEL1L (5 g/ml) (32), rabbit anti-SOX-2 (1:300, Millipore), mouse anti-Nestin (1:50, Millipore), rabbit anti-glial fibrillary acid protein (GFAP; 1:1000, Sigma), rabbit anti-TUBB3 (1:100, Sigma), mouse anti-O4 (1:50, Millipore), mouse anti-Ki-67 clone MIB (1:80, Dako), and rabbit anti-Cleaved CaspaseIII (1:500, Cell Signaling). Proteins were revealed with the appropriate secondary antibodies (Rhodamine Red antimouse IgM and anti-rabbit IgG, Alexa Fluor 488 anti-mouse IgG, Jackson ImmunoResearch). Nuclei were counterstained with Hoechst (Invitrogen). Images were acquired using a NIKON fluorescence microscope (NIKON Microsystems) evaluating at least 800 cells for each sample.
Whole Genome Gene Expression-Triplicate samples from independent experiments were used for whole-genome expression analysis. Briefly, 500 ng of total RNA was amplified and labeled using the Illumina TotalPrep RNA amplification kit (Ambion). 750 ng of labeled cRNA was hybridized on the BeadChip Array Human HT-12 v4.0 (Illumina) at 58°C for 16 h. After hybridization, chips were washed, coupled with Cy3, and scanned in the Illumina BeadArray Reader. Data were processed using BRB-ArrayTools Version 4.2.1. Raw data were logtransformed, normalized by robust spline normalization, and filtered to exclude genes with a p value of the log-ratio variation Ͼ0.05 and with the percentage of data missing or filtered out exceeding 50% and annotated by Bioconductor annotation package lumiHumanAll.db (Version 1.14.0). Class comparison analysis was applied to the 17,548 genes that passed filtering criteria. Functional analysis was achieved using Gene Set Enrichment Analysis (GSEA) software (33) . Data were collapsed using max_probe mode, and supervised analysis was performed on data from VPA-treated cells versus untreated samples. Permutation was executed on genesets 1000 times, weighted statistics were used for enrichment, and the metric for ranking genes was signal2noise. The genesets were from GSEA Molecular Signatures Database v3.0.
Cell Vitality, Colony Formation, and Neurosphere Assays-For the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability assay, GSC lines were plated onto 96-well plates at a density of 2000 cells/well. After 24 h cells were exposed to VPA and exposed to MTT (1 mg/ml) (Invitrogen) for 4 h at 37°C. Formazan release was quantified at 560 nm using a Microplate Reader (Biotek). The data are the average of five measurements from three independent treatments.
For the colony-forming assay, GSC lines were seeded in triplicate in six-well plates at a density of 800 cells/well. After 24 h, cells were exposed to VPA; thereafter, the drug was removed, and fresh medium was added. Colonies were scored after 12 days, fixed in methanol, and stained with 10% Giemsa.
For the neurosphere assay, GSC lines were seeded in duplicate in low attachment six-well plates (Corning) at a density of 3000 cells/well in the absence or presence of VPA. Sphere diameter was calculated from the area of each sphere using ImageJ software, free access by the National Institutes of Health (rsbweb.nih.gov). The data are the averages of three independent experiments.
Immunohistochemistry-Thirty-four glial tumors were studied: 24 glioblastoma multiformes, 3 World Health Organization (WHO) grade II astrocytomas and 2 WHO grade III astrocytomas, 3 WHO grade II and 2 WHO grade III oligodendrogliomas following the (WHO) guidelines (31) . The study was approved by the Ethic Committee of the Azienda Ospedaliera CTO-Maria Adelaide (n. 487/212) of Turin.
Immunohistochemistry was performed on 5-m-thick sections from formalin-fixed paraffin-embedded tissue using antihuman SEL1L mouse monoclonal antibody (1:350) (32) and the anti-human Ki-67/MIB.1 mouse monoclonal antibody (M7240, 1:100, Dako) on a Ventana Full BenchMark automatic immunostainer (Ventana). The UltraView TM Universal DAB detection kit was used. Heat-induced epitope retrieval was performed in Tris-EDTA (pH 8; Ventana).
RESULTS
SEL1L Expression in GSC Lines-SEL1L mRNA and protein were evaluated in five GSC lines (G166, G179, GBM2, GliNS2, and GBM7) (28 -30) . The lowest levels were observed in G166, and the highest levels were observed in GliNS2 and GBM7 (Fig.  1, A and B) . SEL1L followed the expression of SOX2 and that of several ER stress markers ( Fig. 1C ), suggesting a role in indicating ER stress conditions and GSC stemness conditions. SEL1L Knockdown Reduces GSC Line Proliferation and Induces Neural Cell Differentiation-To explore the functional role of SEL1L in GSC lines, the G179 line was transiently nucleofected with two siRNAs against SEL1L (si-SEL1L) and one NT siRNA. Both si-SEL1L down-modulated SEL1L mRNA by at least 50% in the hard-to transfect G179 cell line and elicited the same silenced phenotype. Indeed, SEL1L silencing (50% of the mRNA and about 47% of the protein; Fig. 2 , A1 and A2) impaired the cell proliferative capacity of 37% with respect to control si-NT siRNA cells (p ϭ 0.046, Fig. 2B ) in addition to reduction of neurosphere size (Fig. 2C ).
Interfered cells with the two si-SEL1L also showed: (i) a 32% decrease of Notch1 expression and (ii) a 1.7-fold increase of the neuronal differentiation marker ␤III-tubulin (TUBB3) ( Fig. 2D ) (both genes have previously been described in SEL1L-linked signaling pathways (18, 34, 35) ); (iii) neither SOX2 nor ER stress functional genes were affected ( Fig. 2D ), indicating no off-target effects. Immunofluorescence analysis confirmed TUBB3 increase and unvaried SOX2, Nestin, GFAP, and oligodendrocyte marker O4 ( Fig. 2E ). These data indicate that SEL1L may act as a supporter of GSC proliferation, and its depletion can instruct GSC toward neuronal fate.
VPA Up-regulates SEL1L and UPR Gene Expression in GSC Lines-Histone deacetylase inhibitors, such as VPA, are used in several clinical trials including glioblastoma (8, 9, 36) . Here we explored the effects of VPA on GSC by analyzing the levels of SEL1L and two central UPR-related genes (Bip and Chop) by a qPCR assay. G179 cells were exposed to clinically relevant VPA concentration of 2 mM (37) in a time course manner. The maximum effect was seen after 96 h post-treatment in the G179 line (Fig. 3A) ; hence, G166, GBM2, GliNS2, and GBM7 were assayed at the same time point. SEL1L levels strongly increased in G166 and GBM2 (Fig. 3, B and C) ; interestingly, these cells along with G179 showed the lowest endogenous levels of SEL1L ( Fig. 1A) . On the contrary, the GliNS2 and GBM7 with the highest initial expression ( Fig. 1A) exhibited faint up-modulation of SEL1L after VPA addition ( Fig. 3C ).
We next explored the ability of VPA to exacerbate the preexisting ER stress by monitoring the expression of BIP, the UPR master regulator, and CHOP, the executioner of the pro-apoptotic arm. Although G166, G179, and GBM2 displayed acute UPR activation upon VPA exposure, GliNS2 and GBM7 were moderately affected (Fig. 3D ). The mechanism underlying the disparate UPR/SEL1L activation between cell lines still remains unclear, probably relying on the basal expression levels of the endogenous genes.
The biological relevance of VPA was evaluated using short and long term survival assays. MTT analysis revealed that VPA treatment significantly reduced cells viability by 36.5, 25.3, and 57.3% in G166, G179, and GBM2, respectively, whereas a modest effect was observed in GliNS2 and GBM7 (Fig. 4A) . Among the GSC lines tested, GBM2 were the most responsive to the VPA cytotoxic activity, whereas GliNS2 and GBM7 were the more resistant (Fig. 4A ). GBM2 exhibited, in addition to the aggravation of ER stress (Fig. 3D ), a drastic decrease in SOX2, Notch, and Hedgehog signaling after VPA treatment (Fig. 4B) , indicating that the mys-regulation of these networks may synergistically contribute in reducing protection against cytotoxicity mediated by VPA.
Marked morphological changes were observed in both G166 and G179 after VPA exposure, both in adherent ( Fig. 4C ) and in neurosphere conditions (Fig. 4D) . In adherent conditions, cells 
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increased in volume and in length, whereas in neurosphere, cells grew from rolling spheres to adherent star-shaped cells with numerous cellular protrusions, indicating initial differentiation. A colony formation assay indicated drastic impairment of plating efficiency in both G166 and G179 after VPA exposure (Fig. 4E) . These data indicate that VPA could be a pharmacologic ER stress aggravator able to affect aggressiveness and drug resistance.
Profiling GSC Lines Exposed to VPA-To gain insights into possible molecular mechanisms underlying sensitivity to VPAinduced cytotoxicity and the concomitant decrease in aggressiveness, whole G166 and G179 transcriptome exposed to VPA was profiled using Illumina beadchip arrays. A whole genome expression profile revealed that GSC lines exhibited extensive transcriptional changes as a consequence of VPA treatment. Expression profiles of VPA-treated versus untreated G166 cells revealed a total of 3731 differentially expressed genes at the nominal 0.0001 level of the univariate test, whereas 1568 genes were differentially expressed in VPA treated versus untreated G179 cells with an overlap of 1044 differentially expressed genes in both VPA-treated cells (30 and 67%, respectively) ( Fig. 4F) .
To better understand VPA effects on cell aggressiveness and proliferation, expression profiles from VPA-treated and untreated cells were subjected to functional analysis by GSEA using genesets from Canonical Pathways and Gene Ontology (GO)_Biological Process collections (supplemental Table S1 ). Although the proteasome protein-encoding genes were downmodulated, in both VPA-treated cells the UPR genes were significantly up-modulated ( Fig. 4G , Table 2 and supplemental  Table S1 ). Detailed analyses of UPR genes showed a greater increase of CHOP (DDIT3) and BIP (HSPA5) in VPA-treated cells (Fig. 5, A and B) , confirming previous results.
Gene Ontology analysis highlighted a down-modulation of cell cycle and cell cycle control-encoding genes in VPA-treated samples that paralleled the impaired growth after drug expo-FIGURE 2. The effects of SEL1L silencing in G179 line. A, 1 and 2, SEL1L mRNA and protein silencing efficiency. G179 cell line (1 ϫ 10 6 ) was nucleofected with 1 NT siRNA or 2 si-SEL1L for 48 h, and silencing efficiency was verified by mRNA using qPCR (1) and protein using Western blot (1) and immunofluorescence staining (2) . A1, the histogram shows values normalized relative to housekeeping signals and expressed as-fold modulation relative to controls. The data reflect the average of two si-SEL1L and two independent knockdown experiments. B-E, G179 were treated with NT siRNA or two si-SEL1L for 48 h, harvested and analyzed for the following. B, trypan blue exclusion test. The histogram shows the averages of three independent experiments. Student's t test (p) was used to determine statistical significance. C, neurosphere assay. Cells were plated in six low attached wells (3000 cells/well) and maintained in neurosphere cell conditions for 10 days. The figure is a representative image of three independent experiments. D, qPCR analysis of si-SEL1L-mediated depletion determined a decrease in NOTCH1 expression but a parallel increase in TUBB3 levels. BIP, CHOP, and HRD1 as well as SOX2 and GFAP expression were unchanged after SEL1L depletion. The histogram shows expression values of treated cells normalized relative to housekeeping signals and expressed as -fold modulation relative to untreated samples. E, immunofluorescent analysis. A strong increase of TUBB3 immunoreactivity was observed in si-SEL1L cells with respect to controls. Nestin, SOX2, GFAP, O4, and Hoechst (HO) remained unchanged. sure ( Table 2, supplemental Table S1 and Fig. 4, A and E) . In addition, enrichment of geneset collecting genes related to neuronal development and neuronal differentiation in VPAtreated cells supported that morphological changes of cells exposed to VPA are driven by a differentiated process (Table 1,  supplemental Table S1 and Fig. 4, C and D) .
Eleven genes were chosen for validation by a qPCR assay ( Fig.  3, A, C, and D, and Fig. 5C ). Overall, the two methods of analysis showed good concordance with the exception of few genes (e.g. PTEN and GP78 alias AMFR) that emerged to be slightly different between the transcriptome and gene-specific analysis ( Fig. 5 ). This may be due to the endogenous low expression levels of these genes whose faint expression differences could only be detected through the high sensitivity and specificity of the real-time PCR but not through the stringent criteria used for array expression.
SEL1L Knockdown Affects GSC Line Proliferative and Selfrenewal Potential after VPA Addition-VPA treatment upregulated SEL1L expression in almost all GSC lines under analysis (Fig. 3, A-C) , suggesting the potential protection of SEL1L against VPA cytotoxicity. Here, we examined whether SEL1L down-modulation affected VPA toxicity on G179 FIGURE 3. The effect of VPA on SEL1L and UPR expression. A, SEL1L expression in G179 exposed to VPA treatment was evaluated by qPCR and Western blot analysis in a time course experiment. The histograms shows expression values normalized relative to housekeeping signals and are expressed as -fold modulation relative to untreated G179. B, SEL1L protein levels in G166 exposed to VPA were evaluated by Western blot analysis. The histogram shows expression values normalized relative to housekeeping signals and are expressed as -fold modulation relative to untreated G166. C, SEL1L expression in GSC lines exposed to VPA was analyzed by qPCR. The histogram shows expression values normalized relative to housekeeping signals and are expressed as -fold modulation relative to untreated cells. D, UPR activation in GSC lines exposed to VPA was analyzed by qPCR. The histogram shows expression values normalized relative to housekeeping signals and are expressed as -fold modulation relative to untreated controls.
line. Two si-SEL1L proteins were used to assess the minimal or no off-target activity and the reliability of the silenced phenotype.
Although VPA treatment induced SEL1L mRNA and protein in both mock and interfered cells (a 1.81-fold increase in VPA treated versus untreated NT-siRNA cells and a 2-fold increase in VPA-treated versus untreated si-SEL1L cells), inhibition of about 50 and 40% was preserved both in untreated and treated si-SEL1L cells, respectively, compared with controls ( Fig. 6A, 1  and 2 ). An MTT assay shows that SEL1L depletion in combination with VPA treatment significantly decreased cell survival of about 24% (Fig. 6B) and concomitantly down-modulated the . VPA affects phenotypic and molecular characteristics of GSC lines. A, an MTT assay was applied to evaluate the viability of GSC lines after VPA treatment. The histogram shows cell viability values expressed as -fold modulation relative to untreated samples. p was used to determine statistical significance. B, pPCR of GBM2 VPA-treated. GBM2 were exposed to VPA treatment and analyzed for genes expression using qPCR. The histogram shows expression values of VPA-treated cells normalized relative to the housekeeping gene and are expressed as -fold modulation relative to untreated cell line. C and D, representative images of GSC lines plated on laminin-coated flasks (C) or maintained in neurosphere conditions (D) in the absence or presence of VPA. E, GSC lines (800 cells/well-6) were exposed to VPA and assayed for colony formation. The drug was replaced with fresh growth medium, and cells were allowed to form colonies for a further 12 days. Colonies were stained with Giemsa. The images are representative of three independent treatments. F, a Venn diagram shows the number of overlapping genes differentially expressed in VPA-treated GSC lines. G, UPR and a proteasome heat map in VPA-treated and untreated GSC lines.
TABLE 2 GSEA analysis of gene expression of two GSC lines exposed to VPA
Genesets enriched in VPA-treated and untreated samples. The Enrichement Score represents the degree to which each gene set is overrepresented at the top or bottom of the ranked list of genes in the expression dataset; Normalized Enrichement Score (NES) estimates the enrichment score after it has been normalized across analyzed genesets; NOM p-value estimates the statistical significance of the enrichment score for a single gene set; FDR q-value is adjusted for gene set size and multiple hypotheses testing.
Genesets
Geneset collection number of Ki-67 positive cells, as revealed by antigenic analysis (Fig. 6, C and D) , suggesting that SEL1L abatement played a crucial role in improving drug efficiency specifically in acutely exacerbated stressful conditions. We examined cell death in these cells by assaying for caspase 3 cleavage (data not shown) and by immunoreactivity, which did not indicate pronounced apoptosis (Fig. 6C ). We also examined the effect of SEL1L knockdown combined with VPA treatment on neurosphere formation. As shown in Fig. 6E , the number of neoformed neurospheres was much lower in G179 cells treated with both si-SEL1L and VPA than that observed in control. This indicates that SEL1L knockdown affects the self-renewal process in aggravated ER stress conditions. These results indicate SEL1L as a protector against VPA cytotoxic effect, acting in the maintenance of proliferative and self-renewal potential.
Immunohistochemistry of SEL1L Expression in Human Primary Gliomas-SEL1L expression was evaluated in a small series of primary gliomas. Immunohistochemistry analysis was performed on a total of 34 formalin-fixed paraffin sections of glial tumors (24 glioblastomas, 5 WHO grade II-III astrocytomas, and 5 WHO grade II-III oligodendrogliomas). In glioblas-tomas, a diffuse and variable staining of SEL1L was observed in tumor cells both in the nuclei and cytoplasms. More intense SEL1L immunoreactivity was observed in scattered nuclei (Fig.  7A, 1 and 3) and cytoplasms. which show the same distribution as those positive for Ki-67/MIB.1 (Fig. 7A, 2 and 4) .
Low grade astrocytomas displayed weak SEL1L cytoplasmic and perinuclear expression ( Fig. 7B1 ), but in WHO grade III areas its expression became also nuclear (Fig. 7B2) . The limited number of cases does not allow for a clear correlation with Ki-67/MIB.1 labeling index. In WHO grade II oligodendrogliomas, not more than 5-10% of cells showed a variable positive nuclear, perinuclear, and cytoplasmic staining (Fig. 7C1) . The most intensely stained nuclei correspond to the Ki-67/MIB.1 distribution (Fig.  7C2 ). This is more evident in WHO grade III oligodendroglioma (Fig. 7C, 3 and 4) . Tumor vessel cells and endothelia are positive (Fig. 7D, 1 and 2) . Nonetheless, further work on a higher number of cases is necessary to draw any significant conclusion on the role of SEL1L in glioblastomas. Taken together, the data indicate that SEL1L expression is associated with the histological malignancy grade and that the expression intensity seems to parallel the Ki-67/ MIB.1 distribution. . Effects of si-SEL1L and VPA combined treatments in G179. A, 1 and 2, SEL1L mRNA and protein silencing efficiency after VPA treatment. G179 cell line (1 ϫ 10 6 ) was nucleofected with NT siRNA or two si-SEL1L for 48 h and maintained in the absence or presence of VPA for an additional 4 days. The data reflect the average of two si-SEL1L and two independent knockdown experiments. Silencing efficiency was verified by mRNA using qPCR (1) and protein using immunofluorescent staining (2) . 1, the histogram shows values normalized relative to housekeeping signals and are expressed as -fold modulation relative to controls. HO, Hoechst. B-E, the G179 was treated with NT siRNA or si-SEL1L for 48 h and analyzed as follows. B, MTT cell viability assay. Nucleofected cells were seeded in 96-well plates at a density of 2000. After 24 h, cells were treated with VPA and analyzed for viability. The histogram shows cell viability values expressed as -fold modulation relative to drug-treated (VPA) versus untreated samples. p was used to determine statistical significance. C, Immunofluorescence analysis. Nucleofected cells were seeded on 12-well cover glass and maintained in the absence or presence of VPA for 4 days. A decrease in the number of positive Ki-67 cells was observed in si-SEL1L G179s with respect to control either in the absence or presence of VPA. Scattered areas with faint CASP3 immunoreactivity were observed in treated si-SEL1L G179 cells. D, Ki-67 was evaluated in terms of % of positively stained nuclei counted in at least 800 cells per group. E, Neurosphere assay. Nucleofected cells were seeded in 6 low attachment plates wells at density of 3000 and maintained in neurosphere cell conditions in the absence or presence of VPA for 4 days. Then the culture was allowed to recover from drug treatment by adding fresh medium in excess for an additional 7 days. The figure is a representative image of three independent experiment. p was is used to determine statistical significance.
DISCUSSION
High grade gliomas, especially glioblastoma, are the most aggressive and vascularized brain tumors characterized by high resistance to intensive combined therapies and low median survival rate (38) . Ongoing studies are focusing on overcoming the main therapeutic resistance determinants represented by (i) methylation status of O 6 -methylguanine-DNA methyltransferase, an important mechanism contributing in decreasing the resistance to alkylating agents, (ii) mis-regulation of several complex signaling pathways, (iii) existence of glioma stem-like cells, a small population of brain tumor exhibiting stem cell features and implicated in radio and chemoresistance, (iv) the blood-brain barrier, and (v) angiogenesis (38) .
VPA emerges as a promising therapeutic agent by virtue of its anticancer and antiangiogenesis properties and the capacity to cross the blood-brain barrier with minimal toxicity over long term administration (39 -42) . Being a UPR pathway activator in glioblastoma (11) , VPA may also deregulate protein homeostasis and induce proteotoxic stress, favoring the dominance of the proapoptotic over the adaptive response. Although adaptive and contra-adaptive modulation of UPR may represent a promising strategy for glioblastoma, the impact of this signaling, as well as the downstream targets, in GCS is still neglected.
Here we explore the potential therapeutic advantages of VPA treatment combined with perturbation of the proteostasis network on GSC by targeting SEL1L, a crucial modulator of homeostasis (15) (16) (17) 43) and linked to neural stemness maintenance and lineage determination (18) as well as cancer aggressiveness (19, 21, 43) .
VPA treatment combined with SEL1L interference synergy enhanced the GSC drug sensitivity likely through affecting proliferative and self-renewal properties implicating that SEL1L protein sustain GSC to remain in an undifferentiative state and preserve their stem cell-like features. We hypothesize that SEL1L may be a defensive mechanism adopted by GSC to maintain stemness homeostasis under stressful conditions and highlight the necessity of its abatement to overwhelm the stem cell drug resistance. Impairment of the GSC proliferative rate and neurosphere size occurred when the GSC line was subjected to SEL1L downmodulation. Indeed, SEL1L depletion (i) instructed GSC toward a neuronal rather than astrocytic or oligodendrocyte differentiation and (ii) affected Notch1 signaling, a well known pathway that supports GSC propagation (44) . A direct link between SEL1L and Notch has already been shown in Caenorhabditis elegans whereas it acts as a negative regulator of Lin-12/ Notch activity (34, 45) ; in mammalian cells indirect evidence underscored that SEL1L may regulate pancreatic epithelial growth and differentiation by suppressing Notch-mediated signaling (35) and influence the self-renewal and lineage commitment of the murine neural stem cells likely by mis-regulation of the Notch pathway (18) . Studies are in progress to define whether SEL1L depletion is a direct determinant of the GSC phenotypic reversion or indirect through Notch deregulation. The neuronal commitment of the GSC line in response to SEL1L knockdown seems to be specific in tumor context as neural stem cell depleted for SEL1L exhibited a preferential astrocytic differentiation (18) .
VPA alone affects GSC viability and anchorage-dependent growth likely by inducing the differentiation programs and by affecting the cell cycle progression, as underscored by whole genome analysis. VPA-modulated genes mainly aggregated into the functional categories of "cell cycle mitotic," "cell cycle checkpoints," and "nervous system development." In addition, VPA exacerbated the pre-existing ER stress conditions in GSC, implying it might act as a well established ER stress aggravator of pharmacological compounds. These pharmacological agents have become particularly appealing for potential cancer therapy as, by exacerbating the ER stress, they might promote the switch of the engaged pro-survival response versus the proapoptotic wave of UPR, thus favoring tumor cell death (13) . Consistently, a whole genome expression profile revealed the down-modulation of several genes coding for proteasome components in response to VPA treatment, implying that VPA might drastically compromise the degradation and secretion efficiency with a consequent overload of misfolded protein in the ER lumen and promotion of cell death, similar to the proteasome inhibitors (47) . Among several ER stress aggravators, Gamitrinib-TPP and nelfinavir are inducers of SEL1L protein expression in glioblastoma cell line (48) . 3 Interestingly, VPA cytotoxicity testing on GSC shows different drug responses, stratifying GSC in responders and nonresponders. Among responders, GBM2 displays a strong downmodulation in Notch and Hedgehog pathways, a signaling cascade responsible for cell stemness and survival maintenance as well as chemo/radio-resistance in glioma tumor initiating cell (44, 49, 50) . Although the molecular mechanisms behind VPA action on these networks are currently unclear, our findings indicate a potential link between abatement of these pathways and reduced protection against VPA cytotoxicity. It can be speculated that the VPA effect on GSC viability could partially be a consequence of the interference on Notch/Hedgehog cascades, with important implications in glioma therapy. In sup-port to our findings, several reports underlined the mis-regulation of Notch signaling cascade mediated by VPA as a novel strategy for cancer therapy (46, 51, 52) .
Notably, the SEL1L link with cell proliferation was also observed in primary gliomas where SEL1L distribution and intensity paralleled those of Ki-67 and with tumor grade and proliferation. Interestingly, the SEL1L subcellular localization (nucleus or cytoplasm) may result from SEL1L variant activation in response to genotoxic insults, which is a previously described phenomenon (26, 27) .
In summary, we reported on the synergic effect of SEL1L down-modulation combined with VPA treatment on GSC drug response; although the current study focused on the histone deacetylase inhibitor, SEL1L subversion might have relevance also in association with radiation treatment. Targeting SEL1L and its interacting partners might provide an innovative approach to deplete GSC and improve glioma treatment.
